LITS
Lite Strategy, Inc.1.5200
-0.0100-0.65%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
55.91MP/E (TTM)
-Basic EPS (TTM)
-1.31Dividend Yield
0%Recent Filings
8-K
Launched LTC options, repurchases
Lite Strategy launched its covered call options program on Litecoin holdings, generating nearly $600,000 in gross premiums during the fiscal 2026 Q2 ended December 31, 2025. It kicked off a $25 million stock repurchase using those proceeds, while starting pre-clinical pharma R&D. Cash stood at $8.8 million. Active treasury beats passive holdings.
10-Q
Q2 FY2026 results
Lite Strategy posted a Q2 FY2026 net loss of $30.8M, up from $2.7M y/y, driven by $26.5M change in fair value of digital assets; operating loss hit $29.9M versus $3.5M prior year (derived). No revenue, but Q/Q net loss widened sharply from $3.6M on LTC volatility and covered call collateralization. Cash fell to $8.8M with $64.0M digital assets after $100M LTC buy; $96.6M PIPE funded it, offset by $99.4M investing outflow, while ops used $6.4M. Share repurchases started December at $1.47/share using call premiums. Diluted EPS matches shares at 37.4M. LTC price swings pose the top risk.
8-K
2026 Equity Plan approved
Lite Strategy stockholders approved the 2026 Omnibus Equity Compensation Plan at the February 12, 2026 annual meeting, authorizing 2,000,000 shares plus shares from the expired 2008 Plan. This triggered 455,000 replacement options for Mr. File. Re-elected directors File and Riezman; ratified CBIZ CPAs. New plan aids talent retention.
8-K
File's CEO deal formalized
Lite Strategy formalized Justin File's CEO appointment—plus CFO and Secretary roles—via employment agreement effective November 14, 2025, with $575,000 base salary and 50% target bonus. Severance includes 12 months pay, COBRA, pro-rata bonus, and 12-month option acceleration; full vesting kicks in on change of control. File signed a new proprietary info pact. Locks in leadership continuity.
8-K
Switches auditors to CBIZ
AIBT
Aibotics Inc.
0.00+0.00
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
IMA
ImageneBio, Inc.
6.25+0.08
INTI
Inhibitor Therapeutics Inc.
0.05-0.00
INTS
Intensity Therapeutics, Inc.
0.44+0.02
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
LTRN
Lantern Pharma Inc.
3.33-0.04
MAIA
MAIA Biotechnology, Inc.
1.23-0.12